Market by Type, Delivery Mode, Application, End-user, Sales Channel, and Country Outlook | Forecast 2022-2028
As
per Triton Market Research’s report, the immunoglobulin market in the
Asia-Pacific is likely to grow with a CAGR
of 7.11% in the forecasting years 2022-2028.
Report scope can be customized per your requirements. Request For Customization
The countries analyzed in
this region include:
• India
• China
• Japan
• South Korea
• Australia & New Zealand
• ASEAN Countries
• Rest of Asia-Pacific
The
rapid increase in the geriatric population, increasing prevalence of various
diseases, and enhanced focus on research & development are a few factors
boosting the demand for immunoglobulin across various countries in this region.
In addition, the contribution from several market players in launching advanced
and innovative immunoglobulin products is also fostering the market’s growth.
South
Korea is witnessing a rapid increase in the geriatric population, which is
expected to bolster the growth of the immunoglobulin market. Further, according
to statistics, the geriatric population of the country comprised 3.51 million
males and 4.61 million females in 2020, and this number is expected to reach
8.98 million males and 9.84 million females by 2060. The rise in the elderly
population results in an increased incidence of immunodeficiency diseases and
the severity of various infections. This is expected to accelerate the demand
for immunoglobulin products.
Also,
multiple factors, such as reduced levels of thymic hormones, thymic involution,
and an increase in the number of immature T lymphocytes, are responsible for
altered cells in the population. Thus, to treat such conditions, the adoption
of immunoglobulin products and therapies is on the rise, which is expected to
boost the market’s growth in the near future.
In
Japan, the increasing usage of immunoglobulin for the prevention of chronic
inflammatory demyelination polyneuropathy progression has presented an upward
trend for the market. Top players are developing new and advanced products to
treat multiple diseases and offer therapeutic benefits to patients, thus
contributing to the growth of the immunoglobulin market in the country.
Subcutaneous
immunoglobulin is the human immunoglobulin for subcutaneous use, an injection
needle inserted under the patient’s skin. This delivery mode type is a solution
of human plasma proteins and immunoglobulin G antibodies. Generally, these are
prepared from large pools of human plasma and consist of typical immunoglobulin
G antibodies. In recent years, the administration of immunoglobulin through the
subcutaneous route has become significantly popular. Besides, this further
helps treat autoimmune neurological conditions such as multifocal motor
neuropathy.
The studied report assesses
the market’s growth based on the type, delivery mode, application, end-user,
and sales channel. Here, the delivery mode segment
comprises intravenous, subcutaneous, and intramuscular.
The leading companies
considered in the immunoglobulin market include Bio Products Laboratory,
Shanghai RAAS Blood Products Co Ltd, Kedrion Biopharma, Kamada Ltd, Sanquin
Plasma Products BV, LFB Group, Takeda Pharmaceutical Company Limited, and
Octapharma AG.
China Biologic
Products Inc is a leading biopharmaceutical company that offers a wide range of
plasma-derived products. The company’s core business includes developing,
manufacturing, and selling plasma-derived & other biopharmaceutical
products. The company’s product portfolio comprises 10 plasma-derived products
with more than 20 specifications in human immunoglobulin, human albumin, and
human coagulation factors. Moreover, being a leader in plasma-derived products,
the company possesses advanced technology and world-class R&D capabilities.
It was founded in 2002. China Biologic Products Inc is headquartered in
Chaoyang District, Beijing.
Key deliverables of the report:
● Market CAGR during the forecasting years 2022-2028
● Detailed data highlighting key insights, industry components, and
market strategies
● Comprehensive information and estimation of the immunoglobulin market
revenue growth in Asia-Pacific and its influence on the parent market
● In-depth study of forthcoming trends in consumer behavioral patterns
● A meticulous analysis of the competitive landscape, vendor scorecard,
and Porter’s Five Forces Model
● A wide-ranging study of factors that will challenge the Asia-Pacific
immunoglobulin market’s growth during the upcoming years
Want
to get specific insights? Our team of analysts can customize this report based
on your preferences. Connect with us here.
Market By Type, Application, E ..
VIEW REPORT
Market By Device Type, Therape ..
VIEW REPORT
Market By Type, Application, T ..
VIEW REPORT
Market By Technology, Applicat ..
VIEW REPORT
Market By Application, Type, E ..
VIEW REPORT
Market by Therapeutics, Diagno ..
VIEW REPORT
Market by Type, Application, E ..
VIEW REPORT1. ASIA-PACIFIC
IMMUNOGLOBULIN MARKET – SUMMARY
2. INDUSTRY
OUTLOOK
2.1. IMPACT
OF COVID-19 ON THE IMMUNOGLOBULIN MARKET
2.2. KEY
INSIGHTS
2.2.1. DEVELOPMENT
OF NEW PURIFICATION METHODS
2.2.2. INCREASING
PREFERENCE FOR PERSONALIZED MEDICINES
2.3. PORTER’S
FIVE FORCES ANALYSIS
2.3.1. THREAT
OF NEW ENTRANTS
2.3.2. THREAT
OF SUBSTITUTES
2.3.3. BARGAINING
POWER OF BUYERS
2.3.4. BARGAINING
POWER OF SUPPLIERS
2.3.5. THREAT
OF COMPETITIVE RIVALRY
2.4. MARKET
ATTRACTIVENESS INDEX
2.5. VENDOR
SCORECARD
2.6. KEY
MARKET STRATEGIES
2.6.1. PRODUCT
LAUNCHES & DEVELOPMENTS
2.6.2. PARTNERSHIPS
& AGREEMENTS
2.7. MARKET
DRIVERS
2.7.1. GROWTH
IN THE GERIATRIC POPULATION
2.7.2. PREVALENCE
OF IMMUNODEFICIENCY DISEASES AND AUTOIMMUNE DISORDERS
2.7.3. INCREASING
RESEARCH AND DEVELOPMENT ACTIVITIES
2.8. MARKET
CHALLENGES
2.8.1. HIGH
COST OF THERAPY
2.8.2. HIGH
RISK OF SIDE EFFECTS DUE TO THE USE OF IMMUNOGLOBULIN
2.9. MARKET
OPPORTUNITIES
2.9.1. INCREASING
ADOPTION OF INTRAVENOUS IMMUNOGLOBULIN (IVIG) TREATMENTS
2.9.2. GROWING
CLINICAL TRIALS
3. ASIA-PACIFIC
IMMUNOGLOBULIN MARKET OUTLOOK – BY TYPE
3.1. IGG
3.2. IGA
3.3. IGM
3.4. IGE
3.5. IGD
4. ASIA-PACIFIC
IMMUNOGLOBULIN MARKET OUTLOOK – BY DELIVERY MODE
4.1. INTRAVENOUS
4.2. SUBCUTANEOUS
4.3. INTRAMUSCULAR
5. ASIA-PACIFIC
IMMUNOGLOBULIN MARKET OUTLOOK – BY APPLICATION
5.1. HYPOGAMMA
GLOBULINEMIA
5.2. CHRONIC
INFLAMMATORY DEMYELINATING POLYNEUROPATHY
5.3. PRIMARY
IMMUNODEFICIENCY DISEASES
5.4. MYASTHENIA
GRAVIS
5.5. MULTIFOCAL
MOTOR NEUROPATHY
5.6. IDIOPATHIC
THROMBOCYTOPENIC PURPURA (ITP)
5.7. INFLAMMATORY
MYOPATHIES
5.8. SPECIFIC
ANTIBODY DEFICIENCY
5.9. GUILLAIN-BARRE
SYNDROME
5.10. OTHER
APPLICATIONS
6. ASIA-PACIFIC
IMMUNOGLOBULIN MARKET OUTLOOK – BY END-USER
6.1. HOSPITALS
& CLINICS
6.2. HOMECARE
7. ASIA-PACIFIC
IMMUNOGLOBULIN MARKET OUTLOOK – BY SALES CHANNEL
7.1. HOSPITAL
PHARMACY
7.2. SPECIALTY
PHARMACY
7.3. OTHER
SALES CHANNELS
8. ASIA-PACIFIC
IMMUNOGLOBULIN MARKET – COUNTRY OUTLOOK
8.1. CHINA
8.2. JAPAN
8.3. INDIA
8.4. SOUTH
KOREA
8.5. ASEAN
COUNTRIES
8.6. AUSTRALIA
& NEW ZEALAND
8.7. REST
OF ASIA-PACIFIC
9. COMPETITIVE
LANDSCAPE
9.1. BIOTEST
AG
9.2. CHINA
BIOLOGIC PRODUCTS INC
9.3. GRIFOLS
SA
9.4. LFB
GROUP
9.5. CSL
BEHRING
9.6. KEDRION
BIOPHARMA
9.7. OCTAPHARMA
AG
9.8. TAKEDA
PHARMACEUTICAL COMPANY LIMITED
9.9. BIO
PRODUCTS LABORATORY
9.10. SHANGHAI
RAAS BLOOD PRODUCTS CO LTD
9.11. PFIZER
INC
9.12. SANQUIN
PLASMA PRODUCTS BV
9.13. ADMA
BIOLOGICS
9.14. SICHUAN
YUANDA SHUYANG PHARMACEUTICAL CO LTD
9.15. KAMADA
LTD
10. RESEARCH
METHODOLOGY & SCOPE
10.1. RESEARCH
SCOPE & DELIVERABLES
10.2. SOURCES
OF DATA
10.3. RESEARCH
METHODOLOGY
TABLE 1: ASIA-PACIFIC
IMMUNOGLOBULIN MARKET, BY COUNTRY OUTLOOK, 2022-2028 (IN $ MILLION)
TABLE 2: VENDOR SCORECARD
TABLE 3: ASIA-PACIFIC
IMMUNOGLOBULIN MARKET, BY TYPE, 2022-2028 (IN $ MILLION)
TABLE 4: ASIA-PACIFIC
IMMUNOGLOBULIN MARKET, BY DELIVERY MODE, 2022-2028 (IN $ MILLION)
TABLE 5: ASIA-PACIFIC
IMMUNOGLOBULIN MARKET, BY APPLICATION, 2022-2028 (IN $ MILLION)
TABLE 6: ASIA-PACIFIC
IMMUNOGLOBULIN MARKET, BY END-USER, 2022-2028 (IN $ MILLION)
TABLE 7: ASIA-PACIFIC
IMMUNOGLOBULIN MARKET, BY SALES CHANNEL, 2022-2028 (IN $ MILLION)
TABLE 8: ASIA-PACIFIC
IMMUNOGLOBULIN MARKET, BY COUNTRY OUTLOOK, 2022-2028 (IN $ MILLION)
FIGURE 1: MARKET
ATTRACTIVENESS INDEX
FIGURE 2: ASIA-PACIFIC
IMMUNOGLOBULIN MARKET, BY TYPE, 2021 & 2028 (IN %)
FIGURE 3: ASIA-PACIFIC
IMMUNOGLOBULIN MARKET, BY IGG, 2022-2028 (IN $ MILLION)
FIGURE 4: ASIA-PACIFIC
IMMUNOGLOBULIN MARKET, BY IGA, 2022-2028 (IN $ MILLION)
FIGURE 5: ASIA-PACIFIC IMMUNOGLOBULIN
MARKET, BY IGM, 2022-2028 (IN $ MILLION)
FIGURE 6: ASIA-PACIFIC
IMMUNOGLOBULIN MARKET, BY IGE, 2022-2028 (IN $ MILLION)
FIGURE 7: ASIA-PACIFIC
IMMUNOGLOBULIN MARKET, BY IGD, 2022-2028 (IN $ MILLION)
FIGURE 8: ASIA-PACIFIC
IMMUNOGLOBULIN MARKET, BY DELIVERY MODE, 2021 & 2028 (IN %)
FIGURE 9: ASIA-PACIFIC
IMMUNOGLOBULIN MARKET, BY INTRAVENOUS, 2022-2028 (IN $ MILLION)
FIGURE 10: ASIA-PACIFIC
IMMUNOGLOBULIN MARKET, BY SUBCUTANEOUS, 2022-2028 (IN $ MILLION)
FIGURE 11: ASIA-PACIFIC
IMMUNOGLOBULIN MARKET, BY INTRAMUSCULAR, 2022-2028 (IN $ MILLION)
FIGURE 12: ASIA-PACIFIC
IMMUNOGLOBULIN MARKET, BY APPLICATION, 2021 & 2028 (IN %)
FIGURE 13: ASIA-PACIFIC
IMMUNOGLOBULIN MARKET, BY HYPOGAMMA GLOBULINEMIA, 2022-2028 (IN $ MILLION)
FIGURE 14: ASIA-PACIFIC IMMUNOGLOBULIN
MARKET, BY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY, 2022-2028 (IN $
MILLION)
FIGURE 15: ASIA-PACIFIC
IMMUNOGLOBULIN MARKET, BY PRIMARY IMMUNODEFICIENCY DISEASES, 2022-2028 (IN $
MILLION)
FIGURE 16: ASIA-PACIFIC
IMMUNOGLOBULIN MARKET, BY MYASTHENIA GRAVIS, 2022-2028 (IN $ MILLION)
FIGURE 17: ASIA-PACIFIC
IMMUNOGLOBULIN MARKET, BY MULTIFOCAL MOTOR NEUROPATHY, 2022-2028 (IN $ MILLION)
FIGURE 18: ASIA-PACIFIC
IMMUNOGLOBULIN MARKET, BY IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP), 2022-2028
(IN $ MILLION)
FIGURE 19: ASIA-PACIFIC
IMMUNOGLOBULIN MARKET, BY INFLAMMATORY MYOPATHIES, 2022-2028 (IN $ MILLION)
FIGURE 20: ASIA-PACIFIC
IMMUNOGLOBULIN MARKET, BY SPECIFIC ANTIBODY DEFICIENCY, 2022-2028 (IN $
MILLION)
FIGURE 21: ASIA-PACIFIC
IMMUNOGLOBULIN MARKET, BY GUILLAIN-BARRE SYNDROME, 2022-2028 (IN $ MILLION)
FIGURE 22: ASIA-PACIFIC
IMMUNOGLOBULIN MARKET, BY OTHER APPLICATIONS, 2022-2028 (IN $ MILLION)
FIGURE 23: ASIA-PACIFIC
IMMUNOGLOBULIN MARKET, BY END-USER, 2021 & 2028 (IN %)
FIGURE 24: ASIA-PACIFIC
IMMUNOGLOBULIN MARKET, BY HOSPITALS & CLINICS, 2022-2028 (IN $ MILLION)
FIGURE 25: ASIA-PACIFIC
IMMUNOGLOBULIN MARKET, BY HOMECARE, 2022-2028 (IN $ MILLION)
FIGURE 26: ASIA-PACIFIC
IMMUNOGLOBULIN MARKET, BY SALES CHANNEL, 2021 & 2028 (IN %)
FIGURE 27: ASIA-PACIFIC
IMMUNOGLOBULIN MARKET, BY HOSPITAL PHARMACY, 2022-2028 (IN $ MILLION)
FIGURE 28: ASIA-PACIFIC
IMMUNOGLOBULIN MARKET, BY SPECIALTY PHARMACY, 2022-2028 (IN $ MILLION)
FIGURE 29: ASIA-PACIFIC
IMMUNOGLOBULIN MARKET, BY OTHER SALES CHANNELS, 2022-2028 (IN $ MILLION)
FIGURE 30: ASIA-PACIFIC
IMMUNOGLOBULIN MARKET, COUNTRY OUTLOOK, 2021 & 2028 (IN %)
FIGURE 31: CHINA
IMMUNOGLOBULIN MARKET 2022-2028 (IN $ MILLION)
FIGURE 32: JAPAN
IMMUNOGLOBULIN MARKET 2022-2028 (IN $ MILLION)
FIGURE 33: INDIA IMMUNOGLOBULIN
MARKET 2022-2028 (IN $ MILLION)
FIGURE 34: SOUTH KOREA
IMMUNOGLOBULIN MARKET 2022-2028 (IN $ MILLION)
FIGURE 35: ASEAN COUNTRIES
IMMUNOGLOBULIN MARKET 2022-2028 (IN $ MILLION)
FIGURE 36: AUSTRALIA & NEW
ZEALAND IMMUNOGLOBULIN MARKET 2022-2028 (IN $ MILLION)
FIGURE 37: REST OF
ASIA-PACIFIC IMMUNOGLOBULIN MARKET 2022-2028 (IN $ MILLION)